Navigation Links
Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
Date:11/21/2007

SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Alliance Pharmaceutical Corp. (OTC Bulletin Board: ALLP). Following a Steering Committee meeting last week in China with its partner Beijing Double-Crane Pharmaceutical Co., Ltd. (Double-Crane), Alliance has updated its clinical development plan for Oxygent(TM) (perfluorochemical [PFC] emulsion) to focus primarily on supporting the initial clinical development of Oxygent in China. The clinical development plan for China is to investigate Oxygent in maintaining hemodynamic stability during major surgery, thereby potentially reducing or avoiding intraoperative transfusions of donor blood in major surgery. In addition, the Phase 2 clinical trial in China will incorporate oxygenation endpoints of postoperative improvement of organ function, such as the gut, heart, brain and kidney. As a result, Alliance will discontinue enrollment in the current French study and evaluate a new protocol to correspond to the China Phase 2 study. Alliance is currently transferring the manufacturing technology to enable Double-Crane to manufacture Oxygent in China. Following the manufacture of clinical supplies in China, Double-Crane plans to submit an IND to the sFDA, which is anticipated to be completed in 2008. Alliance will seek additional funding to support this plan.

About Alliance Pharmaceutical Corp.

Alliance is a development-stage pharmaceutical company that is currently focused on developing its lead product, Oxygent, which is based on its proprietary PFC technology. Oxygent is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

Except for historical information, the matters set forth in this release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth herein. Alliance refers you to cautionary information contained in documents Alliance files with the Securities and Exchange Commission from time to time, including the last Form 10-KSB and Form 10-QSB. Alliance is under no obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Alliance Pharmaceutical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 2017  Demonstrating its commitment to representing research- ... the Pharmaceutical Research and Manufacturers of America (PhRMA) ... will now have to meet new research and ... to join PhRMA. "By putting in ... a clear message that being a member of ...
(Date:5/6/2017)... 2017   Provista , a proven leader in the ... today announced Jim Cunniff as the company,s new ... business experience to Provista, including most recently serving as the ... California . He assumed his new role with Provista ... fit for Provista," says Jody Hatcher , president, Sourcing ...
(Date:5/4/2017)... Clarius Mobile Health, a digital healthcare ... this week at the American Congress of Obstetricians ... San Diego, CA from May ... perfect tool for clinicians to easily confirm pregnancy, ... pregnancy-related complications like ectopic pregnancy and placenta previa," ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming new ... Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on patients’ ... longer need to feel the esthetic effects of wires and brackets when they can ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... female reproductive tract in which the endometrial lining of the uterus spreads ... and pain. Patients experiencing painful intercourse, painful periods, pelvic pain, or irregular ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Rob Lowe is ... “Informed,” developed for Public Television. “Informed” brings the public important topics from all aspects ... treatment of the feet and issues surrounding feet and ankles. , Podiatry is essential ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a leading ... that its iClinic V12.2 solution has achieved approval from National Center for Quality ... 2017 standards which emphasize team-based care with a significant focus on the care ...
(Date:5/23/2017)... ... , ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations and ... Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s Regulations ... today reported on a new study released on May 21, 2017 in the New ...
Breaking Medicine News(10 mins):